The Case for Ashwagandha: Where the Evidence Stands and Where the Market Is Heading

India — 16 August 2026

Ashwagandha, the adaptogenic darling of the wellness industry, is frequently lauded for its stress-reducing prowess. But does the pervasive marketing narrative truly align with the nuanced scientific evidence, particularly regarding cortisol management? While consumer demand for stress relief solutions continues its upward trajectory, formulators must critically examine whether the hype around Ashwagandha translates into reliably efficacious products with defensible claims, or if we are merely witnessing another ingredient riding a wave of anecdotal enthusiasm.

What the Clinical Evidence Actually Shows

Clinical investigations into Ashwagandha's anxiolytic and stress-modulating effects often cite a reduction in perceived stress and serum cortisol levels. A prominent 2012 study by Chandrasekhar et al., for instance, reported a significant reduction in serum cortisol (around 27%) in subjects receiving a high-concentration full-spectrum root extract (300mg twice daily) compared to placebo. Similarly, a 2019 review by Speers et al. highlighted several trials showing benefits across various stress scales, typically using doses ranging from 300mg to 600mg of root extract daily, often standardised to 2.5-5% withanolides. However, the picture is not uniformly clear. Many studies suffer from small sample sizes, short durations, and heterogeneity in extract types and standardisation methods. Conflicts of interest are also a consideration, with a notable proportion of research funded by ingredient manufacturers. As Dr. Anya Sharma, a pharmacognosy researcher, recently noted,

"While promising, the evidence base for Ashwagandha's direct cortisol-lowering effect is still maturing. We need more independent, large-scale, long-term trials with consistent extract specifications to move beyond correlation to definitive causation."

The Formulation Reality

Formulating with Ashwagandha is not without its challenges. Bioavailability is a critical concern; the primary bioactive compounds, withanolides, have variable absorption rates. Optimal forms typically involve high-concentration root extracts, often standardised to a minimum of 2.5% total withanolides, with some premium extracts reaching 5% or higher. Water-soluble extracts are gaining traction for improved absorption profiles. Excipient interactions must be carefully considered, as certain binders or fillers could impede dissolution or stability. Shelf stability is another technical detail requiring attention; withanolides can degrade over time, particularly when exposed to light, heat, or moisture. Packaging, therefore, plays a crucial role. For instance, a capsule formulation might offer superior protection compared to a powder blend in a pouch, ensuring the product retains its claimed potency throughout its shelf life. Formulators must also contend with the distinct, somewhat bitter taste of some extracts, which requires careful masking in palatability-focused applications.

Market Position and Commercial Viability

The Ashwagandha market is experiencing robust growth, driven by increasing consumer awareness of adaptogens and stress management. Industry analysts project the global Ashwagandha market to exceed £150 million by 2027, growing at a CAGR of over 10%. This demand, however, leads to pricing pressures and a crowded supplier landscape. While bulk powdered root material may seem cost-effective, formulators seeking validated claims will invariably opt for premium, standardised extracts, which command higher prices. Minimum Order Quantities (MOQs) for these specialised extracts can range from 25kg to 100kg, impacting smaller brands. Achieving competitive margins requires astute sourcing and efficient manufacturing processes. "The market has matured beyond basic Ashwagandha powder," comments Mr. Rajeev Gupta, a procurement specialist. "Brands must invest in high-quality, clinically backed extracts to differentiate, even if it means accepting a slightly tighter initial margin for the long-term brand equity." Lead times for specialty extracts can also fluctuate based on harvest cycles and supplier capacity, necessitating careful inventory planning.

What This Means for India

India, as the native home and primary producer of Ashwagandha (Withania somnifera), holds a unique position. The regulatory context, governed by bodies such as AYUSH and FSSAI, supports its traditional use, but modern supplement claims still require substantiation. Domestically, consumer demand for Ayurvedic remedies is deeply ingrained, providing a foundational market. However, the competitive landscape is intensifying, with both established pharmaceutical companies and agile start-ups vying for market share. There is a growing emphasis on sustainable sourcing and organic certification, driven by global export demands and increasingly discerning local consumers. Indian manufacturers are well-placed to leverage their proximity to raw materials and traditional knowledge, but must also embrace advanced extraction technologies and robust quality control to meet international standards and capitalise on the ingredient's global appeal.

The Bottom Line for Formulators

Formulators should invest in Ashwagandha, but with discernment. Focus on clinically validated, high-concentration root extracts, standardised to at least 2.5% withanolides, to support stress and cortisol management claims. Be prepared for higher raw material costs and MOQs associated with premium ingredients. Prioritise stability and bioavailability in formulation development. The market rewards efficacy and transparency, so ensure your claims are defensible against the specific extract and dosage used. Ashwagandha remains a commercially viable ingredient for stress support, provided the formulation is evidence-led and robustly executed.

Warm regards,

PANACEA